Inside Drugmakers’ Strategy to Boost Cancer Medicines with ‘Lazarus Effect’
September 9, 2019
(Reuters) – In the halls of MD Anderson Cancer Center, the drug Vitrakvi is known for having a “Lazarus effect” in some patients because it can reverse late-stage cancer that has defied all other treatment options. Developed by Eli Lilly and Co’s (LLY.N) Loxo Oncology and marketed by German drugmaker Bayer (BAYGn.DE), it fights a rare genetic mutation that appears in less than 1% of solid tumors, regardless of where they appear in the body. Finding those patients will require widespread adoption of sophisticated tests that look for multiple genetic alterations that could be driving the cancer.